{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:45:12Z","timestamp":1792471512018,"version":"4.5.0"},"reference-count":87,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>\n                    Until recently, the treatment of metastatic castration-resistant prostate cancer (mCRPC) relied exclusively on hormonal therapies and taxane chemotherapy. The advent of modern molecular profiling methods applied in the clinic, namely, next-generation sequencing and advanced positron emission tomography (PET) imaging, has allowed for the development of biomarker-driven therapeutics including anti\u2013PD-L1 therapy for microsatellite instability-high or tumor mutation burden-high disease, poly(ADP-ribose) polymerase (PARP) inhibitors for patients with DNA damage repair mutations, and lutetium 177 vipivotide tetraxetan (\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617) for patients with prostate-specific membrane antigen (PSMA) PET-avid disease. While these targeted therapies have improved outcomes, there is an opportunity to refine biomarkers to optimize patient selection, understand resistance, and develop novel combination strategies. In addition, studies in the laboratory and in patient-derived samples have shown that a subset of mCRPC tumors lose expression of common prostate cancer markers such as prostate-specific antigen and PSMA because of lineage plasticity and the development of non\u2013androgen receptor (AR)-driven disease. Non\u2013AR-driven prostate cancer has been associated with aggressive behavior and poor prognosis, including in some cases histologic transformation to a poorly differentiated neuroendocrine prostate cancer (NEPC). The clinical management of NEPC typically follows the treatment paradigm for small cell lung cancer and increasingly relies on genomic and phenotypic characterization of disease, including loss of tumor suppressors and expression of cell surface markers such as DLL3. Therefore, both genomic subtyping and phenotypic subtyping are important to consider and can guide the clinical management of patients with advanced prostate cancer.\n                  <\/jats:p>","DOI":"10.1200\/edbk-25-473636","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:08:14Z","timestamp":1742490494000},"source":"Crossref","is-referenced-by-count":15,"title":["State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1200","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9006-7043","authenticated-orcid":false,"given":"Wassim","family":"Abida","sequence":"first","affiliation":[{"name":"Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5801"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3403"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001065"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603144"},{"key":"e_1_3_4_8_2","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","author":"Abida W","unstructured":"Abida W, Armenia J, Gopalan A, et al: Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 10.1200\/PO.17.00029","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4805"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01035"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0394"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.021"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00757-9"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00376-4"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214676"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022485"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.024"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0108"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0172"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00393-y"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aam7479"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01649"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01055-3"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02704-x"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00382-0"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1402"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30365-6"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.LBA18"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.5005"},{"key":"e_1_3_4_32_2","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver DA","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, et al: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81-85, 1997","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1682"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-015-0114-2"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1485"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.47251"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00605-2"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102862"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00274-6"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05160-8"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.262250"},{"key":"e_1_3_4_46_2","article-title":"Genomic correlates of prostate-specific membrane antigen expression and response to 177Lu-PSMA-617: A retrospective multicenter cohort study","author":"Raychaudhuri R","unstructured":"Raychaudhuri R, Mo G, Tuchayi AM, et al: Genomic correlates of prostate-specific membrane antigen expression and response to 177Lu-PSMA-617: A retrospective multicenter cohort study. JCO Precis Oncol 10.1200\/PO.23.00634","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00424-2"},{"key":"e_1_3_4_48_2","article-title":"Exceptional response to 177Lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects","author":"Crumbaker M","unstructured":"Crumbaker M, Emmett L, Horvath LG, et al: Exceptional response to 177Lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects. JCO Precis Oncol 10.1200\/PO.18.00237","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104131"},{"key":"e_1_3_4_50_2","article-title":"Cancer-control outcomes of patients with metastatic castration-resistant prostate cancer with BRCA gene or tumor suppressor mutations undergoing 177-lutetium prostate-specific membrane antigen radioligand therapy","author":"Wenzel M","unstructured":"Wenzel M, Koll F, Hoeh B, et al: Cancer-control outcomes of patients with metastatic castration-resistant prostate cancer with BRCA gene or tumor suppressor mutations undergoing 177-lutetium prostate-specific membrane antigen radioligand therapy. JCO Precis Oncol 10.1200\/PO-24-00645","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223099"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0226"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00900-z"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.030"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.242057"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231179309"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/53\/7\/007"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-020-00301-2"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00135-9"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00009-9"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05392-2"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-019-0174-x"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265194"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264144"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268363"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00149"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10020188"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1423"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0019"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.01.043"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4045"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2061"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-01003-9"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0225"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.09.003"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe1505"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00539-6"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3791"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30408-5"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.9096"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102172"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307980"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0754"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3762"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02605-z"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-2052"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161858"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-473636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T21:12:38Z","timestamp":1746047558000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-473636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/EDBK-25-473636"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-473636","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"e473636"}}